A phase 1 clinical trial evaluating JIN-A04 for NSCLC
Latest Information Update: 12 Feb 2023
At a glance
- Drugs JIN A04 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
Most Recent Events
- 12 Feb 2023 New trial record
- 06 Feb 2023 According to a J Ints Bio media release, the company plans to submit an IND to the US and Korea in the first half of this year, allowing us to enter this phase 1 study.